Physician profile
Mark Prebonich
NPI 1912094442
$1,606.16
in general payments reported to CMS, 2019-2025
20 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $95.06 · 2024: $752 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.17 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $294.94 | 2023-2024 | Watchman Flx |
| Abbvie INC. | $196.38 | 2024-2025 | |
| Insmed, INC. | $194.83 | 2025 | Arikayce |
| Abbott Laboratories | $192.32 | 2024-2025 | Mitraclip, Freestyle Libre 3 |
| Exact Sciences Corporation | $148.64 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $114.58 | 2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $82.29 | 2024-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $48.11 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Mozarc Medical US LLC | $41.36 | 2024 | Palindrome |
| Sanofi-Aventis U.S. LLC | $40.36 | 2025 | |
| Inari Medical, INC. | $34.22 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sumitomo Pharma America, INC. | $34.17 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $31.47 | 2025 | Breztri, Farxiga |
| Eisai INC. | $29.99 | 2025 | |
| Janssen Pharmaceuticals, INC | $25.14 | 2024 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.80 | 2024 | |
| Horizon Therapeutics Plc | $21.27 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $19.88 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.44 | 2025 | Keveyis |
| Amgen INC. | $14.97 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Prebonich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.